Clinicians and researchers offering early access to Grail’s multi-cancer early detection (MCED) test are waiting for the full NHS trial readout after the endpoint miss, according to the report. The discussion centers on whether the test is ready for wider implementation ahead of FDA regulatory decisions. The situation underscores how trial endpoint design and data interpretation are shaping access decisions in national health systems, even when regulators are not yet finished. The reporting indicates that medical teams are scrutinizing limitations and debating readiness as evidence updates approach.